Teva Pharmaceutical Industries Ltd (TEVA)

32.41
0.49 1.50
NYSE : Health Care
Prev Close 31.92
Open 32.12
Day Low/High 32.03 / 32.74
52 Wk Low/High 27.59 / 55.79
Volume 5.74M
Avg Volume 8.26M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 32.46B
EPS 0.10
P/E Ratio 6.22
Div & Yield 1.36 (4.30%)

Latest News

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

Rumors swirled that Pascal Soriot would leave for rival Teva Pharmaceuticals.

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Neither company has confirmed Pascal Soriot's move.

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European benchmarks held gains much of Thursday.

Teva Enhances Board Of Directors As All Proposals Approved At Annual General Meeting Of Shareholders

Teva Enhances Board Of Directors As All Proposals Approved At Annual General Meeting Of Shareholders

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today.

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca shares dropped in the first hours of trading Thursday after it was reported that Teva Pharmaceuticals was courting its CEO.

Teva Stock Jumps as New CEO Expected to Be Named

Teva Stock Jumps as New CEO Expected to Be Named

AstraZeneca CEO Pascal Sorio will reportedly take over at Teva.

Teva To Report Second Quarter 2017 Financial Results On August 3, 2017

Teva To Report Second Quarter 2017 Financial Results On August 3, 2017

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2017 financial results on Thursday, August 3, 2017 at 6:30 a.

Teva And The Huntington Study Group Announce Publication Of Data For AUSTEDO™ (deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology

Teva And The Huntington Study Group Announce Publication Of Data For AUSTEDO™ (deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and the Huntington Study Group today announced results from the Phase III open-label, single-arm switch cohort of the ARC-HD ( Alternatives for Reducing Chorea in...

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents

UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents

Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.

Pharma Firms Hit With Lawsuit From Oklahoma AG Over Opioid Marketing

Pharma Firms Hit With Lawsuit From Oklahoma AG Over Opioid Marketing

Oklahoma Attorney General Mike Hunter alleged that the firms engaged in misleading marketing practices and "waged a fraudulent, decade-long marketing campaign to profit from the anguish of thousands of Oklahomans."

Celltrion And Teva Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Rituxan® (rituximab)

Celltrion And Teva Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Rituxan® (rituximab)

Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd.

Teva Announces Publication Of AIM-TD Study Results In The Lancet Psychiatry For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia

Teva Announces Publication Of AIM-TD Study Results In The Lancet Psychiatry For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of results from the Phase III study, AIM-TD ( A ddressing I nvoluntary M ovements in T ardive D yskinesia), in the...

Technology Might Be About to Change the Healthcare Industry Forever

Technology Might Be About to Change the Healthcare Industry Forever

Technology might be about to change the healthcare industry forever, or at least according to Teva Pharmaceutical's CEO.

Teva And Xenon Announce Phase II Study Of Topical TV-45070 In Patients With Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

Teva Ready for Higher Prices

Teva Ready for Higher Prices

The money flow has turned positive.

Chart of the Day: Teva

The money flow has turned positive.

FDA Commissioner Takes on Big Pharma

FDA Commissioner Takes on Big Pharma

Investors should watch these companies come July 18th.

Teva Pharmaceuticals Upgraded at Mizuho

Teva Pharmaceuticals Upgraded at Mizuho

Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Teva Announces Launch Of Generic Zetia® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Zetia ®1 (ezetimibe) tablets, 10 mg, in the U.

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.

Teva Pharmaceutical Stock Rising on Generic Eye Drop Launch

Teva Pharmaceutical Stock Rising on Generic Eye Drop Launch

The drops are used to treat itchy eyes associated with allergies.